S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Nemus Bioscience Stock Price, News & Analysis (OTCMKTS:NMUS)

Today's Range N/A
50-Day Range
$0.26
MA: $0.31
$0.41
52-Week Range N/A
Volume54,090 shs
Average Volume494,554 shs
Market Capitalization$38.95 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.04
Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryCannabis
SectorMedical
Current SymbolOTCMKTS:NMUS
CUSIPN/A
CIKN/A
Phone949-396-0330

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.12) per share

Profitability

Net Income$-19,190,000.00

Miscellaneous

EmployeesN/A
Market Cap$38.95 million
Next Earnings DateN/A
OptionableNot Optionable

Receive NMUS News and Ratings via Email

Sign-up to receive the latest news and ratings for NMUS and its competitors with MarketBeat's FREE daily newsletter.


Nemus Bioscience (OTCMKTS:NMUS) Frequently Asked Questions

What is Nemus Bioscience's stock symbol?

Nemus Bioscience trades on the OTCMKTS under the ticker symbol "NMUS."

How were Nemus Bioscience's earnings last quarter?

Nemus Bioscience Inc (OTCMKTS:NMUS) issued its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.09) EPS for the quarter. View Nemus Bioscience's Earnings History.

Has Nemus Bioscience been receiving favorable news coverage?

Press coverage about NMUS stock has been trending somewhat negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nemus Bioscience earned a daily sentiment score of -1.9 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Nemus Bioscience.

Who are some of Nemus Bioscience's key competitors?

What other stocks do shareholders of Nemus Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nemus Bioscience investors own include Canopy Growth (CGC), Emerald Health Therapeutics (EMHTF), Medmen Enterprises (MMNFF), 22nd Century Group (XXII), Aurora Cannabis (ACBFF), KushCo (KSHB), CannaRoyalty (ORHOF), Terra Tech (TRTC), Cronos Group (CRON) and mCig (MCIG).

Who are Nemus Bioscience's key executives?

Nemus Bioscience's management team includes the folowing people:
  • Dr. Brian S. Murphy, CEO, Chief Medical Officer & Director (Age 61)
  • Dr. Avtar S. Dhillon, Exec. Chairman (Age 57)
  • Mr. Douglas A. Cesario, Chief Financial Officer (Age 44)
  • Ms. Wendy Cunning, VP of Bus. Operations

How do I buy shares of Nemus Bioscience?

Shares of NMUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

How big of a company is Nemus Bioscience?

Nemus Bioscience has a market capitalization of $0.00. View Additional Information About Nemus Bioscience.

What is Nemus Bioscience's official website?

The official website for Nemus Bioscience is http://www.nemusbioscience.com/.

How can I contact Nemus Bioscience?

Nemus Bioscience's mailing address is 130 NORTH MARINA DRIVE, LONG BEACH CA, 90803. The biopharmaceutical company can be reached via phone at 949-396-0330.


MarketBeat Community Rating for Nemus Bioscience (OTCMKTS NMUS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  131
MarketBeat's community ratings are surveys of what our community members think about Nemus Bioscience and other stocks. Vote "Outperform" if you believe NMUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NMUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel